Edition:
United Kingdom

Kyorin Holdings Inc (4569.T)

4569.T on Tokyo Stock Exchange

2,059JPY
6:00am GMT
Change (% chg)

¥-15 (-0.72%)
Prev Close
¥2,074
Open
¥2,072
Day's High
¥2,077
Day's Low
¥2,054
Volume
191,600
Avg. Vol
207,317
52-wk High
¥2,583
52-wk Low
¥2,054

Latest Key Developments (Source: Significant Developments)

Kyorin Holdings says integration of production function
Tuesday, 19 Dec 2017 

Dec 19(Reuters) - Kyorin Holdings Inc <4569.T>:Says its Tokyo-based drug unit, which was established in October, will take over Noshiro plant of unit Kyorin Pharmaceutical Company, Limited and manufacture division of KYORIN Rimedio Co.,Ltd., effective April 1, 2018.Says the Tokyo-based drug unit will merge with the company's Shiga-based unit KYORIN Pharmaceutical Facilities Co.,Ltd, effective April 1, 2018.Says KYORIN Pharmaceutical Facilities Co.,Ltd will be dissolved after the merger .  Full Article

Kyorin Holdings unit signs production and marketing license agreement with vietnamese pharmaceutical company
Wednesday, 22 Nov 2017 

Nov 22(Reuters) - Kyorin Holdings Inc <4569.T>:Says its subsidiary KYORIN Rimedio Co., Ltd. has agreed to provide a production and marketing license for generic medicine to BinhDinh Pharmaceutical and Medical Equipment JSC.Says pursuant to the terms of the license agreement, KYORIN Rimedio will license the production rights for Losarhyd Combination Tablets LD and two other products to BIDIPHAR in return for a one-time lump sum payment upon conclusion of the agreement and KYORIN Rimedio will also receive royalties.  Full Article

KYORIN Holdings unit grants MSD K.K. manufacturing and marketing rights for medicine of allergic diseases
Wednesday, 28 Sep 2016 

KYORIN Holdings Inc <4569.T>:Says MSD K.K. received a manufacturing and marketing approval for DESALEX® Tablets 5mg for the treatment of allergic diseases from the co's unit KYORIN Pharmaceutical Co., Ltd..  Full Article

Kaken Pharmaceutical to co-promote allergic medicine with Kyorin Holdings unit
Monday, 11 Jul 2016 

Kaken Pharmaceutical Co Ltd <4521.T>:Says the company entered into basic agreement with Kyorin Holdings Inc <4569.T>'s unit on co-promotion of an allergic medicine, whose exclusive sales right is owned by the Kyorin Holdings's unit.  Full Article

KYORIN Holdings unit to sign exclusive distribution agreement
Wednesday, 25 May 2016 

KYORIN Holdings Inc <4569.T>:Says company MSD to grant subsidiary KYORIN Pharmaceutical an exclusive distribution license for an allergic disease treatment drug in Japan changed from joint marketing.  Full Article

Kyorin and Kissei sign agreement for co-development and co-marketing of KRP-114V
Wednesday, 30 Mar 2016 

Kyorin Holdings Inc:KYORIN Pharmaceutical Co., Ltd., a wholly-owned subsidiary of KYORIN Holdings, Inc. and Kissei Pharmaceutical Co., Ltd. jointly announced a co-development and co-marketing agreement for an overactive bladder medication of KRP-114V (INN: Vibegron) which is being developed by Kyorin in Japan.  Full Article

Kyorin Holdings expects extraordinary loss for FY 2016
Tuesday, 23 Feb 2016 

Kyorin Holdings Inc:Says it expects an extraordinary loss of 2.7 billion yen for FY ending March 2016.Says the loss is recorded for the close of pharmaceutical factory.  Full Article

Kyorin Holdings amends consolidated full-year outlook for FY 2016
Wednesday, 3 Feb 2016 

Kyorin Holdings Inc:Says the company amended the consolidated full-year outlook for the FY ended March 2016.Confirmed the revenue at 120,200 million yen.Operating profit forecast increased to 19,400 million yen from 16,000 million yen.Ordinary profit forecast increased to 19,700 million yen from 16,300 million yen.Net profit forecast increased to 13,000 million yen from 11,500 million yen.Earnings per share forecast increased to 175.39 yen from 155.51 yen.Says license agreement and extraordinary profit are the main reasons for the forecast.  Full Article

Kyorin Holdings announces cancellation of license regarding KRP-AB1102F
Wednesday, 3 Feb 2016 

Kyorin Holdings Inc:Subsidiary KYORIN Pharmaceutical Co., Ltd resolved to cancel license agreement with AstraZeneca UK Limited regarding COPD therapeutic KRP-AB1102F.  Full Article

BRIEF-Kyorin Holdings says integration of production function

* Says its Tokyo-based drug unit, which was established in October, will take over Noshiro plant of unit Kyorin Pharmaceutical Company, Limited and manufacture division of KYORIN Rimedio Co.,Ltd., effective April 1, 2018